NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / Business News / Glenmark Pharmaceuticals stock falls
    Glenmark Pharmaceuticals stock falls
    Business

    Glenmark Pharmaceuticals stock falls

    Written by Shreyashi
    August 25, 2015 | 08:47 am 3 min read
    Glenmark Pharmaceuticals stock falls

    Glenmark's stock closed at Rs.1,164.80, down Rs.60.55, or 4.94% on the Bombay Stock Exchange on Monday, 24 Aug night. This fall came after the shares of Glenmark Pharma plunged more than 6% on Monday when the brokerage arm of Bank of America Merrill Lynch (BoAML) downgraded the stock to underperform and revised the target price to Rs.1,200 per share.

    Indian high flyer

    Glenmark Pharmaceuticals is an Indian company headquartered in Mumbai, with four manufacturing facilities in the states of Maharashtra, Goa, Himachal Pradesh and Gujarat in India. It has also expanded to 95 other countries including the USA and the UK.

    Glenmark share prices soar

    The United States Food & Drug Administration (USFDA) gave the go ahead for Drospirenone and Ethinyl Estradiol tablets USP, 3 mg/0.02 mg developed by Glenmark Pharmaceuticals Inc.,USA. The company's stock prices soared immediately after the company released this information, reaching a high of Rs.1,187 on the Bombay Stock Exchange. Glenmark plans to start shipping these two new drugs immediately.

    Drospirenone and Ethinyl Estradiol what?

    The newly approved drugs are actually the generic version of Yaz tablets. Yaz tablet is a birth control pill that combines estrogen and progesterone to prevent pregnancy by preventing ovulation. This tablet can also be used to treat acne in females above the age of 14 years or even complaints like symptoms of premenstrual dysphoric disorder, such as anxiety, depression, irritability, trouble concentrating etc.

    Glenmark looks forward to a productive year

    Glenmark expects USFDA approval for 4-6 products during this fiscal year; 8 have been approved already. Among them is Teneligliptin, a new third generation oral anti-diabetic agent which can be used to manage Type 2 Diabetes Mellitus, which Glenmark is marketing under two brands, Ziten and Ziten Plus. At Rs.19.90 per tablet, it offers a cheaper treatment for a diabetic patient using Gliptin tablets.

    Glenmark steps up game in India

    Glenmark looks to launch around 10 products in India this year and will be focussing on key areas like the dermatology, diabetes, cardiology and respiratory segments. India makes up 26% of the company's sales; 31% comes from USA, which is Glenmark's largest market. Among the four categories mentioned, Glenmark will be taking special interest in dermatology. It will launch two drugs for oncology soon.

    Glenmark listed on stock exchange

    Glenmark got listed on the stock exchange in 2000 and has since not looked back, going on to be chosen 'Best Company Across Emerging Markets', 2011 and 'Best Pharma Company in the World – SME', 2008 by SCRIP, a reputed pharma magazine.

    Share this timeline
    Facebook
    Whatsapp
    Twitter
    Linkedin
    Next News Article

    Love Business News?

    Subscribe to stay updated.

    Business Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023